Apolipoprotein E (APOE) ɛ4 allele carriers have an increased risk of late-onset Alzheimer’s disease (AD). However, in the “Choosing Wisely” campaign for avoiding unnecessary medical tests, treatments, and procedures, APOE genetic testing is not recommended as a predictive test for AD.
Objective:
The aim of this study was to investigate the potential value of APOE genetic testing in a specific clinical context.
Methods:
Subjects with poor performance in the Korean version of the Mini-Mental Status Examination for dementia screening (MMSE-DS) with a Z-score of less than –1.5 were recruited from the public health centers. All participants underwent APOE genetic testing. Family history of dementia (FHx) was confirmed if one or more first-degree relatives had dementia.
Results:
Among 349 subjects, 162 (46.4%) were diagnosed with AD. APOEɛ4 allele carriers had a much higher risk of AD in the group with FHx than in the group without FHx (OR = 15.81, 95% CI = 2.74–91.21 versus OR = 1.82, 95% CI = 1.00–3.27, z = 2.293, p = 0.011). The sensitivity, specificity, positive predictive value, and negative predictive value for the APOEɛ4 allele were 47.7%, 90.9%, 91.3%, and 46.5% in the group with FHx.
Conclusion:
It would be a wise choice to perform the APOE genetic testing for the diagnosis of AD in subjects with poor performance in a screening test and a family history of dementia.
ZhuCW, SanoM (2006) Economic considerations in the management of Alzheimer’s disease. Clin Interv Aging1, 143.
3.
SaundersAM, StrittmatterWJ, SchmechelD, George-HyslopPH, Pericak-VanceMA, JooSH, RosiBL, GusellaJF, Crapper-MacLachlanDR, AlbertsMJ, HyletteC, CrainB, GoldgaberD, RosesAD (1993) Association of apolipoprotein E allele ∈4 with late-onset familial and sporadic Alzheimer’s disease. Neurology43, 1467–1467.
4.
CorderEH, SaundersAM, StrittmatterWJ, SchmechelDE, GaskellPC, SmallGW, RosesAD, HainesJL, Pericak-VanceMA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science261, 921–923.
5.
RosesAD (1996) Apolipoprotein E alleles as risk factors in Alzheimer’s disease. Annu Rev Med47, 387–400.
6.
AshfordJW (2008) Screening for memory disorders, dementia and Alzheimer’s disease. Aging Health4, 400–432.
7.
SaundersAM, HuletteO, Welsh-BohmerKA, SchmechelDE, CrainB, BurkeJR, AlbertsMJ, StrittmatterWJ, BreitnerJC, RosenbergC (1996) Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer’s disease. Lancet348, 90–93.
8.
TsuangD, LarsonEB, BowenJ, McCormickW, TeriL, NochlinD, LeverenzJB, PeskindER, LimA, RaskindMA, ThompsonML, MirraSS, GearingM, SchellenbergGD, KukullW (1999) The utility of apolipoprotein E genotyping in the diagnosis of Alzheimer disease in a community-based case series. Arch Neurol56, 1489–1495.
9.
Welsh-BohmerKA, GearingM, SaundersAM, RosesAD, MirraS (1997) Apolipoprotein E genotypes in a neuropathological series from the Consortium to Establish a Registry for Alzheimer’s Disease. Ann Neurol42, 319–325.
10.
CasselCK, GuestJA (2012) Choosing wisely: Helping physicians and patients make smart decisions about their care. JAMA307, 1801–1802.
Van DuijnCM, ClaytonD, ChandraV, FratiglioniL, GravesAB, HeymanA, JormAF, KokmenE, KondoK, MortimerJA, RoccaWA, ShalatSL, SoininenH, HofmanA (1991) Familial aggregation of Alzheimer’s disease and related disorders: A collaborative re-analysis of case-control studies. Int J Epidemiol20, S13–S20.
13.
FratiglioniL, AhlbomA, ViitanenM, WinbladB (1993) Risk factors for late-onset Alzheimer’s disease: A population-based, case-control study. Ann Neurol33, 258–266.
FarrerLA, CupplesLA, Van DuijnCM, KurzA, ZimmerR, MüllerU, GreenRC, ClarkeV, ShoffnerJ, WallaceDC, ChuiH, FlanaganSD, DuraR, Georg- HyslopP, AuerbachSA, VolicerL, WellsJM, BroeckhovenCV, GrowdonJH, HainesJL (1995) Apolipoprotein E genotype in patients with Alzheimer’s disease: Implications for the risk of dementia among relatives. Ann Neurol38, 797–808.
16.
HuangW, QiuC, von StraussE, WinbladB, FratiglioniL (2004) APOE genotype, family history of dementia, and Alzheimer disease risk: A 6-year follow-up study. Arch Neurol61, 1930–1934.
17.
KimTH, JhooJH, ParkJH, KimJL, RyuSH, MoonSW, ChooIH, LeeDW, YoonJC, DoYJ, LeeSB, KimMD, KimKW (2010) Korean version of mini mental status examination for dementia screening and its’ short form. Psychiatry Investig7, 102–108.
18.
LeeJH, LeeKU, LeeDY, KimKW, JhooJH, KimJH, LeeKH, KimSY, HanSH, WooJI (2002) Development of the Korean Version of the Consortium to Establish a Registry for Alzheimer’s Disease Assessment Packet (CERAD-K) clinical and neuropsychological assessment batteries. J Gerontol B Psychol Sci Soc Sci57, P47–P53.
19.
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, Fourth edition, American Psychiatric Association, Washington, DC.
20.
RoccaWA, HofmanA, BrayneC, BretelerMM, ClarkeM, CopelandJR, DartiquesJF, EngedalK, HagnellO, HeerenTJ (1991) The prevalence of vascular dementia in Europe: Facts and fragments from 1980–1990 studies. Ann Neurol30, 817–824.
21.
WenhamPR, PriceWH, BlundellG (1991) Apolipoprotein E genotyping by one-stage PCR. Lancet337, 1158–1159.
22.
FarrerLA, BrinMF, ElsasL, GoateA, KennedyJ, MayeuxR, MyersRH, ReillyP, RischNJ (1995) Statement on use of apolipoprotein E testing for Alzheimer disease. JAMA274, 1627–1629.
23.
JhooJH, KimKW, SuhYJ, LeeDY, YounJC, LeeJH, WooJI (2004) The gender-and age dependency of the risk for Alzheimer’s disease conferred to apolipoprotein E polymorphism in Koreans. Psychiatry Invest1, 56–60.
24.
DawEW, PayamiH, NemensEJ, NochlinD, BirdTD, SchellenbergGD, WijsmanEM (2000) The number of trait loci in late-onset Alzheimer disease. Am J Hum Genet66, 196–204.
25.
StrittmatterWJ, SaundersAM, SchmechelD, Pericak-VanceM, EnghildJ, SalvesenGS, RosesAD (1993) Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A90, 1977–1981.
26.
VerghesePB, CastellanoJM, HoltzmanDM (2011) Apolipoprotein E in Alzheimer’s disease and other neurological disorders. Lancet Neurol10, 241–252.
27.
FarrerLA, CupplesLA, HainesJL, HymanB, KukullWA, MayeuxR, MyersRH, Pericak-VanceMA, RischN, Van DuijnCM (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: A meta-analysis. JAMA278, 1349–1356.
28.
KimKW, JhooJH, LeeKU, LeeDY, LeeJH, YounJY, LeeBJ, HanSH, WooJI (1999) Association between apolipoprotein E polymorphism and Alzheimer’s disease in Koreans. Neurosci Lett277, 145–148.
29.
FratiglioniL (1996) Epidemiology of Alzheimer’s disease and current possibilities for prevention. Acta Neurol Scand Suppl94, 33–40.
30.
JarvikG, LarsonEB, GoddardK, SchellenbergGD, WijsmanEM (1996) Influence of apolipoprotein E genotype on the transmission of Alzheimer disease in a community-based sample. Am J Hum Genet58, 191–200.
31.
ScarabinoD, GambinaG, BroggioE, PellicciaF, CorboRM (2016) Influence of family history of dementia in the development and progression of late-onset Alzheimer’s disease. Am J Med Genet B NEuropsychiatr Genet171, 250–256.
32.
NoguchiS, MurakamiK, YamadaN, PayamiH, KayeJ, HestonLL, BirdTD, SchellenbergGD (1993) Apolipoprotein E genotype and Alzheimer’s disease. Lancet342, 737–738.
33.
ZubenkoGS, StifflerS, StablerS, KoppU, HughesHB, CohenBM, MoossyJ (1994) Association of the apolipoprotein E ɛ4 allele with clinical subtypes of autopsy-confirmed Alzheimer’s disease. Am J Med Genet54, 199–205.
34.
TyasSL, ManfredaJ, StrainLA, MontgomeryPR (2001) Risk factors for Alzheimer’s disease: A population-based, longitudinal study in Manitoba, Canada. Int J Epidemiol30, 590–597.
35.
LaunerLJ, AndersenK, DeweyME, LetenneurL, OttA, AmaducciLA, BrayneC, CopelandJR, DartiguesJF, Kragh-SorensenP, LoboA, Martinez-LageJM, StijnenT, HofmanA (1999) Rates and risk factors for dementia and Alzheimer’s disease: Results from EURODEM pooled analyses. Neurology52, 78–78.
36.
ZintlM, SchmitzG, HajakG, KlünemannHH (2009) ApoE genotype and family history in patients with dementia and cognitively intact spousal controls. Am J Alzheimers Dis Other Demen24, 349–352.
37.
MaestreG, OttmanR, SternY, GurlandB, ChunM, TangMX, ShelanskiM, TyckoB, MayeuxR (1995) Apolipoprotein E and Alzheimer’s disease: Ethnic variation in genotypic risks. Ann Neurol37, 254–259.
38.
RubinszteinDC, EastonDF (1999) Apolipoprotein E genetic variation and Alzheimer’s disease. a meta-analysis. Dement Geriatr Cogn Disord10, 199–209.
